Introduction
IL-6 is a key regulator of host immune and in¯ammatory responses. It is involved in the stimulation of B-and T-lymphocytes, in hematopoiesis, and in the induction of acute phase response (for reviews see references Akira et al., 1993; Heinrich et al., 1990) . On target cells IL-6 acts via a receptor complex composed of a ligand binding 80 kDa glycoprotein (IL-6R) and a 130 kDa signal transducing receptor subunit (gp130), both of which belong to the hematopoietin receptor superfamily (Hirano et al., 1994) . Soluble forms of the IL-6R are generated by alternative splicing or shedding and act as potent agonists of IL-6 on many target cells, including cell types with no IL-6R expression (RoseJohn and Heinrich, 1994) . Dimerization of gp130 on activated cells leads to the activation of intracellular signaling cascades initiated by tyrosine phosphorylation of the STAT3 protein by JAK1, JAK2 and and TYK2 kinases (LuÈ tticken et al., 1994; Stahl et al., 1994) .
The expression of cytokine genes by transfected tumor cells has been used as a strategy to enhance immune responses against various cancers (Pardoll, 1995; Tepper and Mule, 1994) . Tumor cells expressing cytokines, e.g. TNF-a (Blankenstein et al., 1991) , IL-2 (Gansbacher et al., 1990) , IL-6 (Mule et al., 1990 , 1992a Mullen et al., 1992; Porgador et al., 1992) and GM ± CSF (Drano et al., 1993) have been shown to promote the generation of tumor speci®c T-lymphocytes or to induce non-T-cell-mediated mechanisms of tumor cell killing, such as granulocytic in¯ammatory responses. For IL-6 it has been shown that the addition of the soluble IL-6R resulted in a signi®cant enhancement of biological activities in many cell types (Peters et al., 1996a) . This has been exploited in experimental and clinical studies using heterologous IL-6 and sIL-6R gene transfected tumor cells (Mackiewicz et al., 1995a,b) .
Examples for experimental systems are human nonsmall cell lung carcinoma cell lines (Ganapathi et al., 1996) , human breast carcinoma cells (Novick et al., 1992) and B-78 and B16 murine melanoma cells (Mackiewicz et al., 1995b; Oh et al., 1997) . The low immunogenic B16 melanoma was shown to undergo growth inhibition after transfection with IL-6 cDNA (Sun et al., 1992) . This eect was also demonstrated in an in vitro assay using recombinant IL-6 in combination with sIL-6R . In vivo IL-6 exhibits antimetastatic activities on B16 cells (Katz et al., 1993) and again addition of sIL-6R enhances this eect (Mackiewicz et al., 1995c) .
We have recently designed a fusion protein consisting of human IL-6 and the human sIL-6R connected by a¯exible polypeptide chain, termed Hyper-IL-6 (H-IL-6). This fusion protein has been shown to be highly active on hematopoietic stem cells and other gp130 expressing cells Klouche et al., 1999; Peters et al., 1998) . To investigate the antitumorigenic potential of H-IL-6 in vivo we transfected B16 melanoma cells with the cDNA coding for this protein. We demonstrate in this report that transfection of B16 cells with H-IL-6 leads to a dramatic growth inhibition in vitro and a nearly complete tumor rejection in vivo. Furthermore, we show that the antitumorigenic eect of H-IL-6 is partially dependent on GM ± CSF.
Results
Transfection of H-IL-6 cDNA into B16 melanoma cells B16 cells were cotransfected with a plasmid carrying the cDNA for the IL-6/sIL-6R fusion protein under control of the CMV promoter (Figure 1a) , and with the pSV2-neo plasmid (Southern and Berg, 1982) . Thirty neo resistent clones were screened for expression of the H-IL-6 protein by testing the activity of cell supernatants on BAF3/gp130 cells. Two positive clones and one mock-transfected clone carrying only the pSV2-neo plasmid were chosen for this study. Figure  1b shows the expression of the 84 kD glycoprotein of a positive transfectant as detected by immunprecipitation of the radiolabelled protein from the supernatant by an anti-IL-6 antibody. Negative transfectants and parental B16 cells did not secrete H-IL-6 into the medium (data not shown). Figure 1c shows a Western blot analysis of the medium from transfected and parental B16 cells after 10-fold concentration. The IL-6/sIL-6R fusion protein was detected by the anti-IL-6 antibody as eectively as recombinant IL-6. There was no cross reaction of the IL-6 mAB with sIL-6R (right lane). Levels of H-IL-6 in the supernatant of transfected cells were determined by measuring bioactivity of the fusion protein on a BAF3 cell line transfected with gp130 (BAF3/gp130) (Figure 2b ). Untransfected BAF3 cells do not express gp130 and IL-6R and therefore do not respond to IL-6 or H-IL-6 (data not shown). Cell supernatants of transfected B16 cells were harvested after 24 h and a dose-dependent proliferation of BAF3/gp130 cells was observed. The EC 50 concentration was determined as 0.2 ml/ml (Figure 2b ). This corresponds to H-IL-6 levels of 500 pg/ml/10 7 cells/ 24 h (Figure 2a) . The in vivo biological activity and stability of H-IL-6 was tested by i.p. injection of 2 mg of recombinant H-IL-6 in C57BL/6 mice. The expression of the acute phase protein gene haptoglobin was analysed after 72 h by determining serum levels by Western blot analysis ( Figure 2c ). Upon IL-6 injection, after 72 h no elevated haptoglobin levels were detected (data not shown) . Eight of nine mice tested showed markedly elevated haptoglobin levels compared to control animals which received PBS. We had shown earlier that H-IL-6-induced acute phase proteins in RPMI mice at much lower concentrations and in a signi®cantly sustained manner as compared to IL-6 . Haptoglobin mRNA levels were shown to peak after 12 ± 24 h after injection with H-IL-6 and still be recognizable after 72 h . Our experiment shows that this holds true for C57BL/6 mice and con®rms the prolonged half life of H-IL-6 in our in vivo model.
In vitro properties of parental B16 cells and transfectants
To test whether H-IL-6 transfection aects cell growth in vitro, proliferation assays were performed and cell densities were determined by colorimetric assay using MTT. Figure 3a shows proliferation of parental B16 and transfected B16/H-IL-6 cells measured at dierent time points over a period of 5 days. Cell growth was markedly inhibited in B16/H-IL-6 cells and cell densities were about 10% of those of parental B16 cells at the end of the time course. Furthermore transfected B16 cells exhibited an altered morphology characterized by elongated cell protrusions, loss of pigmentation and alignment in long arrays indicating an altered dierentitation state ( Figure 3b ). Similar eects were seen when B16 cells were treated with recombinant IL-6/sIL-6R fusion protein . Additionally, measurement of MHC-I showed no dierence between parental B16 cells and transfectants indicating that the low immunogenic status due to low MHC-I expression of transfected B16 cells was not altered by the transfection procedure and the expression of H-IL-6 (Figure 4 ).
In vivo tumor growth
Tumorigenicity of H-IL-6 transfectants was assayed by s.c. injection in syngeneic C57BL/6 mice. Figure 5a shows that B16/H-IL-6 cells produced dramatically smaller tumors than parental or mock-transfected B16 cells. Six out of eight animals in the B16-H-IL-6 group exhibited complete rejection of the tumor cells after 2 weeks. Mean volume of established tumors in this group was 50 ± 100 mm 3 whereas parental or mocktransfected B16 cells produced tumors of 1.800 and 1.900 mm 3 , respectively. In a parallel experiment we looked for survival of mice injected s.c. with parental or transfected B16 cells (Figure 5b ). Fifty per cent of the animals that received B16 cells were moribund and had to be sacri®ced after 3 weeks. No animal in this group survived day 33 after injection, whereas eight of 10 mice that had received B16/H-IL-6 cells survived after 89 days. To test whether a reduced growth of B16 cells induced by recombinant H-IL-6 could be observed in vivo we injected mice that had received parental B16 cells i.p. with 2 mg of recombinant H-IL-6 per animal three times a week. After 2 weeks mice were sacri®ced and tumor weights were deter- Rejection of B16/H-IL-6 cells is impaired in mice transgenic for a GM ± CSFR-antagonist GM ± CSF has been suggested to play a key role in tumor cell rejection by the immune system (Pardoll, 1995) . To investigate the role of GM ± CSF in the rejection of H-IL-6-secreting B16 melanoma cells we injected transfected and parental B16 cells in mice transgenic for the mutated K14E/E21K GM ± CSF protein. This GM ± CSF mutein had previously been shown to bind to the GM ± CSF receptor a-chain but not to stimulate the signal transducing b subunit of the 5 H-IL-6-transfected or parental B16 cells GM ± CSF receptor complex. Therefore, the K14E/ E21K GM ± CSF protein behaved as a GM ± CSF receptor antagonist (Altmann and Kastelein, 1995) . Mice transgenic for the K14E/E21K GM-CSF antagonist showed levels of 2 ± 15 ng/ml in the serum ( Figure  6a ). Transgenic and non-transgenic control mice were sacri®ced after 2 weeks and tumor volumes were determined as described above. Tumor growth of B16/H-IL-6 cells in wild type FVB/N x C57BL/6 mice was comparable to that in C57BL/6 mice with an average tumor volume of 50 ± 100 mm 3 . Tumor volumes in transgenic GM ± CSF K14E/E21K transgenic animals were one order of magnitude (average 900 mm 3 ) higher than in non-transgenic control animals indicating that the rejection of the transfected tumor cells was dependent on the presence of biologically active GM ± CSF (Figure 6b) . Tumors produced by parental B16 cells both in transgenic and wild type mice were comparable to those in C57BL/6 mice.
Discussion
IL-6 is a cytokine that elicits a broad range of immune and acute phase responses. It acts as a dierentiation factor for T-and B-cells and promotes the expansion of early haematopoietic stem cells (Akira et al., 1993) . Altered IL-6 serum levels have been reported for several diseases, including plasmacytoma (Suematsu et al., 1992) , rheumatoid arthritis (Hermann et al., 1989 ), Castleman's Disease (Brandt et al., 1990) and AIDS (Poli et al., 1990) . Furthermore, it has been shown in mice that levels of endogenous IL-6 paralleled with tumor burden indicating an important role of IL-6 in the host's immune responses to cancer (McIntosh et al., 1989) . Anti-tumor activity of IL-6 was demonstrated in a variety of tumor models and suggested its application in experimental and clinical tumor therapy trials (Mule et al., 1990 (Mule et al., , 1992b . Early studies with tumor cells transfected with an IL-6 cDNA showed anti-tumor eects predominantly in vivo and only marginal eects in vitro, possibly due to the lack of soluble IL-6R (Porgador et al., 1992; Sun et al., 1992) . Mackiewicz et al. (1995b) ®rst evaluated the role of the sL-6R in an anti-cancer therapy model using mouse B78-H1 cells. These studies demonstrated that addition of the sIL-6R resulted in an enhanced biological activity of IL-6 in the context of host immune response against cancer cells. Further evidence for the biological activity of the soluble IL-6R came from studies of transgenic mice expressing either IL-6, soluble IL-6R or coexpressing IL-6 and sIL-6R (Peters et al., 1996b (Peters et al., , 1997 Schirmacher et al., 1998) . These data demonstrated that the combination of IL-6 and sIL-6R resulted in an increased bioactivity as compared with IL-6 or sIL-6R alone.
We have recently constructed a designer cytokine consisting of IL-6 and the sIL-6R connected by ā exible polypeptide linker and characterized its in vivo and in vitro activities Peters et al., 1998) . This fusion protein was shown to be 100 ± 1000-fold more active than the separate proteins IL-6 and sIL-6R and displayed a signi®cantly longer plasma half-life, due to impaired internalization by target cells .
This study investigates the anti-tumor potential of this designer cytokine in a murine melanoma model using B16 cells. B16 cells transfected with the H-IL-6 cDNA exhibited an almost linear growth curve in comparison to an exponential proliferation of nontransfected cells. B16/H-IL-6 cells showed inhibition of melanogenesis and alterations in cell shape and growth pattern in vitro. The observed reduction of melanogenesis might be explained by cytokine-induced activation of NF-kB which has been shown to be responsible for the inhibition of tyrosinase expression in B16 cells (Englaro et al., 1999) . Growth inhibition of B16 cells and morphological alteration towards a dendrite-like shape were also observed by other groups after exposing B16-F10.9 cells to IL-6 in combination with sIL-6R or to a recombinant IL-6/sIL-6R fusion protein Oh et al., 1997) .
When H-IL-6-transfected B16 cells were injected in C57BL/6 mice, nearly complete rejection was observed after 2 weeks whereas parental and mock transfected a b Figure 6 Reduced growth inhibition of B16/H-IL-6 cells in mice transgenic for a GM ± CSFR-antagonist. (a) Serum levels of the K14E/E21K GM ± CSF protein in wild type and transgenic mice as detected by ELISA. (b) Eight transgenic (strain tg2) and eight wild type FvB/BL76 mice were injected s.c. with 5610 5 B16/H-IL6 cells and tumor growth was determined after 2 weeks as described above. As control transgenic and wildtype mice were injected with 5610 5 parental B16 cells B16 cells produced tumors of 1.800 mm 3 of average volume. Survival of mice inoculated with B16/H-IL-6 cells was prolonged signi®cantly and 8/10 animals in this group were tumor-free after 89 days. The observed in vitro growth inhibition of transfected cells accounts only partially for this in vivo eect as other B16/H-IL-6 clones exhibiting no growth inhibition after stable H-IL-6 transfection produced similar tumor rejection results (data not shown).
Cell surface expression of MHC-I is a prerequisite of direct cell killing by primed CTLs. H-2K b expression of B16 cells was shown to be downregulated but inducible after IFN-a treatment (Wu and Fleischmann, 1998) . To investigate whether H-IL-6 expression in¯uenced cell surface expression of H-2K b of B16 cells we performed ow cytometric analysis using anti-H-2K b -antibody. Both, transfected and parental B16 cells were H-2K b -negative indicating that the immunonogenic state of the transfected cells was unaltered and direct priming of T-cells via MHC may be ruled out as a possible mechanism of tumor rejection. Instead, the recently recognized potential of H-IL-6 to promote, in combination with GM ± CSF, the massive expansion and subsequent dierentiation of hematopoietic progenitor cells into functional antigen presenting dendritic cells in vitro (Bernhard et al., 2000) led us to investigate the role of GM ± CSF in the rejection process in vivo. Transgenic mice overexpressing a GM ± CSF receptor antagonist and wild-type littermates were injected with B16/H-IL-6 cells. We observed that tumor growth in wildtype mice was comparable to that in C57BL/6 mice whereas the rejection of B16/H-IL-6 cells in transgenic animals was impaired, indicating that the H-IL-6-induced immune response against B16 cells are dependent on the presence of biologically active GM ± CSF. The in vivo tumor growth of parental B16 cells was not in¯uenced by the presence of a GM ± CSF receptor antagonist.
There is growing evidence that IL-6 is involved in the generation of MHC-restricted and -unrestricted antitumor immune responses by T-lymphocytes (Greene et al., 1997; Mullen et al., 1992; Porgador et al., 1992) . Greene et al. (1997) could demonstrate that the development and MHC-unrestricted tumoricidal activity of anti-CD3-activated killer T cells was dependent on IL-6. The long systemic persistance of the secreted H-IL-6 demonstrated in our study would suggest an enhanced activity of such cells in response to H-IL-6 in their microenvironment as a possible mechanism of the observed antitumor eect. GM ± CSF lacks primary activity on T cells. Instead, it improves tumor antigen processing and presentation on professional antigenpresenting cells (APCs) such as macrophages, monocytes and dendritic cells. These eects result in turn in enhanced CD4 and CD8 eector function (Drano et al., 1993) . We demonstrate in our study that blockage of GM ± CSF by a receptor antagonist signi®cantly compromises the rejection of H-IL-6-secreting B16 cells but not that of untransfected B16 cells.
The results have encouraged us to perform a phase I/II clinical trial with promising results. The genetically modi®ed tumor vaccine which consisted of a mixture of irradiated Mich-1 melanoma cells transduced with IL-6/sIL-6R genes and irradiated autologous tumour cells was so far administered to 152 melanoma patients. Mich-1 cells are HLA-A1/A2 positive and are therefore compatible with a high percentage of the Eurasian population. The outline of the trial and preliminary results have recently been described (Nawrocki et al., 2000) .
We conclude that the designer cytokine H-IL-6 shows a promising antitumorigenic potential. Moreover, the combined eect of H-IL-6 and GM ± CSF which should lead to antitumor activity together with increased development of antigen-presenting cells such as dendritic cells might lead to the development of novel therapeutic anti-tumor strategies.
Materials and methods

Plasmid generation and transfection procedures
The H-IL-6 cDNA was produced using the pCDM8-sIL-6R and pCDM8-IL-6 vectors from which the sIL-6R and IL-6 cDNAs were generated by PCR. The linker cDNA was introduced using XhoI sites at the COOH-terminus of the sIL-6R and at the NH 2 -terminus of IL-6. H-IL-6 cDNA was religated into the pCDM8 vector using an NH 2 -terminal NotI and a COOH-terminal HindIII site. The B16/H-IL6 cell line was prepared by transfection with 20 mg of the plasmid vector pCDM8-H-IL-6 in combination with 2 mg of the pSV2Neo plasmid by coprecipitation with calcium phosphate. Detection and biological activity of H-IL-6 in the supernatant of B16/H-IL-6 cells 10 7 B16/H-IL-6 cells were metabolically labelled overnight with 50 mCi/ml [ 35 S]methionine/cysteine in methionine/cysteine free medium and H-IL-6 was immunoprecipitated with an anti-IL-6 antibody bound to Protein A Sepharose. For a Western blot 10 7 B16/H-IL-6 cells were incubated for 24 h with 5 ml of medium containing 0.1% FCS. The supernatant was removed and concentrated 10-fold. Ten ml of the concentrated supernatant were taken for Western blot analysis using the anti-IL-6 antibody mAB-8 (CLB, Amsterdam, The Netherlands).
Cell cultures and assays
Cells were grown in DMEM at 5% CO 2 in a water saturated atmosphere. All cell culture media were supplemented with 10% FCS, 100 mg/ml streptomycin, and 60 mg/l penicillin. Proliferation of B16 and B16/H-IL-6 cells was measured in 96-well microplates (10 000 cells/well/0.1 ml). Viable cell density was determined after 24, 48, 72, 96 and 120 h by the MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay of mitochondrial succinate dehydrogenase. Morphological alterations of B16/H-IL-6 cells were determined after growing cells on chamber slides (NUNC, Naperville, IL, USA) for 48 h. Micrographs were done in a dierential interference contrast (CID) mode with a 200-fold magni®cation. Animals C57BL/6 mice were maintained in a 12-h light, 12-h dark cycle under standard conditions and were provided with food Oncogene Cytokine mediated rejection of melanoma cells S O È zbek et al and water ad libitum. Procedures involving animals and their care were conducted in conformity with national and international laws and policies.
Generation of GM ± CSF receptor antagonist transgenic mice
The cDNA coding for murine GM ± CSF (Gough et al., 1984) was modi®ed in accordance with the published amino acid changes K14E and E21K (Altmann and Kastelein, 1995) . This cDNA was inserted into the keratin 10 expression vector (Blessing et al., 1996) and used for pronuclear microinjection of fertilized eggs of mice of strain FVB/N, essentially as described (Hogan, 1986) . Ospring were biopsied at ears or tails and analysed by PCR using a bovine keratin 10-speci®c primer (5'-TAA CAC ATG TGG GAT ACA CCC-3'; position 1021 ± 1042; GenBank accession no X02870) and a murine GM ± CSF cDNA-speci®c oliginucleotide (5'-CTG GCT GTC ATG TTC AAG GCG-3'; position 218 ± 198; GenBank accession no. X05906) (A Mann, K Breuhan, P Schirmacher, A Wilhemi, C Beyer, A Rosenau, Suat O È zbek, S Rose-John and M Blessing, manuscript submitted for publication). The mice used for the tumor challenging experiments were F1 crosses of FVB/N GM-CSF receptor antagonist transgenics and C57BL/6 mice. The experiments were done with the strain tg2.
Subcutaneous challenge experiment
Mice were shaved on the back and challenged subcutaneously with 10 5 B16 or B16/H-IL-6 cells in PBS. Tumor growth was monitored by measuring perpendicular diameters. Mice were killed after 2 weeks or when the tumors displayed severe necrosis or reached a size of 300 mm 2 . All tumors were excised and evaluated by weighing and volume determination.
Flow cytometric analysis
B16 and B16/H-IL-6 cells were washed twice with PBS (0.1% Tween) and indirect immuno¯uorescence staining was performed by incubating the cells with a FITC-conjugated monoclonal anti-H-2K B D b antibody (Cedar Lane, Hornby, Ontario, Canada) at 48C for 30 min. After washing the cells twice with PBS (0.1% Tween) Flow cytometric analyses were performed using a FACScan (Becton Dickinson, Mountain View, CA, USA). Debris and dead cells were gated out and live cells were plotted using the FACSan Lysis II software (Becton Dickinson, Mountain View, CA, USA). As a control, the same experiment was performed using an IgG2 speci®c antibody.
